Nature and Shanghai Jiao Tong University have each opened investigations into a February 2026 research paper after reports that a child who underwent an experimental gene-editing treatment died, and that the study failed to disclose funding connected to the child's family [1].
According to Retraction Watch, the patient was a six-year-old who died of an immune reaction. The paper, whose corresponding author is Zilong Qiu, omitted roughly $860,000 in funding from the family from its disclosures [1].
A Nature spokesperson, Aranda, confirmed the review is open rather than concluded. "We are now investigating concerns that have been raised around this manuscript," the spokesperson said [1].
Nothing here is settled. Both investigations are ongoing, and the central questions, whether the death was reported appropriately and whether an undisclosed financial relationship shaped the work, have not been adjudicated. Naming what has and has not been established matters more than usual in a case like this.
What is on the record is limited and grave. A six-year-old is dead. A leading journal and a major university are both examining the paper. The funding the paper disclosed did not include a substantial payment connected to the patient's family. Those three facts are the story as of now, and each of them is a reason the reviews exist.
The reason disclosure rules are not a formality sits in exactly this gap. Researchers, regulators and families weighing an experimental treatment rely on the published record being complete. When a death and a six-figure financial tie are absent from that record, the people who most need accurate information to make a decision are the ones left without it.
